Neuphoria Therapeutics (NASDAQ:NEUP) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Neuphoria Therapeutics (NASDAQ:NEUP) from a hold rating to a strong sell rating in a research note published on Monday,Zacks.com reports.

A number of other analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. Maxim Group lifted their price objective on shares of Neuphoria Therapeutics from $18.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Finally, HC Wainwright lowered their target price on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, December 5th. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $21.00.

Neuphoria Therapeutics Price Performance

Shares of NASDAQ NEUP opened at $4.21 on Monday. Neuphoria Therapeutics has a one year low of $2.77 and a one year high of $21.40. The business’s 50-day moving average price is $7.83 and its two-hundred day moving average price is $8.35. The company has a market capitalization of $22.65 million, a P/E ratio of -0.86 and a beta of 0.51.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings results on Friday, November 14th. The company reported ($4.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, equities analysts anticipate that Neuphoria Therapeutics will post -1.56 EPS for the current year.

Insider Activity

In other news, major shareholder Lynx1 Capital Management Lp bought 639,110 shares of the stock in a transaction that occurred on Tuesday, October 21st. The shares were acquired at an average cost of $5.14 per share, for a total transaction of $3,285,025.40. Following the purchase, the insider owned 875,328 shares of the company’s stock, valued at $4,499,185.92. This represents a 270.56% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Neuphoria Therapeutics

An institutional investor recently bought a new position in Neuphoria Therapeutics stock. Millennium Management LLC bought a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 18,329 shares of the company’s stock, valued at approximately $216,000. Millennium Management LLC owned 0.78% of Neuphoria Therapeutics at the end of the most recent reporting period. 15.90% of the stock is owned by institutional investors and hedge funds.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.